ECTRIMS 2018
ECTRIMS 2018 DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.

ECTRIMS 2018 Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.

ECTRIMS 2018 Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.

ECTRIMS 2018 High-Dose Biotin May Be an Effective Treatment for Progressive MS

High-Dose Biotin May Be an Effective Treatment for Progressive MS

Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.

ECTRIMS 2018 Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS

Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS

In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.

ECTRIMS 2018 MS Relapse Rates After DMT Initiation Similar Between Pediatric-, Adult-Onset MS

MS Relapse Rates After DMT Initiation Similar Between Pediatric-, Adult-Onset MS

Disability progression is slower among patients with pediatric-onset multiple sclerosis.

ECTRIMS 2018 Patients With Multiple Sclerosis Face Greater Infection Risk

Patients With Multiple Sclerosis Face Greater Infection Risk

Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.

ECTRIMS 2018 Disease Modifying Therapy Associated With Persistent Brain Atrophy Slowing in MS

Disease Modifying Therapy Associated With Persistent Brain Atrophy Slowing in MS

Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.

ECTRIMS 2018 Alemtuzumab Improves Disability, Prognosis in Treatment-Refractory MS

Alemtuzumab Improves Disability, Prognosis in Treatment-Refractory MS

Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.

ECTRIMS 2018 Fingolimod Significantly Improves Quality of Life in Pediatric MS

Fingolimod Significantly Improves Quality of Life in Pediatric MS

The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.

Upcoming Meetings

Sign Up for Free e-newsletters